Introduction
Honey has long been used as a natural treatment in wound repair and has increased in popularity with antibiotic resistance increase. 1−4 Honey is effectual and costeffective, and its healing properties are well documented. 5−6 Honey can decrease healing time via a dual effect on the inflammatory response. It suppresses the production and proliferation of inflammatory cells at the wound site, to prevent a prolonged inflammatory response, and it stimulates proinflammatory cytokine production, enabling normal healing to occur. 7−11 Wound healing is a tissue remodeling process, comprising a systematic progression of events involving multiple interactions that are regulated by biologically active cytokines, growth factors, and proteases. 12−15 The transcription factor nuclear factor-kappa beta (NF-KB) is an important marker of inflammation. 16 It enhances proinflammatory activity, thereby contributing to an amplified inflammatory response, and activates genes encoding for proinflammatory cytokines -interleukin (IL)-6, IL-8, and tumor necrosis factor-α (TNF-α). 8, 17 These proinflammatory cytokines stimulate nitric oxide production, an important mediator of inflammation. Nitric oxide production 150 Tomblin et al and NF-KB activation are inhibited by the flavonoids present in honey. 18 When healing is impaired, chronic wounds develop, characterized by proinflammatory cytokines and reactive oxygen species. 8,19−22 Honey's effectiveness in wound care has been hypothesized to be largely due to its anti-inflammatory action. 8 The specific compounds and the mechanisms involved are largely undetermined. 23 However, it has been suggested that specific polyphenols, the flavonoids, and caffeic acid phenethyl ester, are important factors. 24−26 The antioxidants found in honey are considered to be important determinants of its anti-inflammatory activity. 2 An elevated inflammatory response results from hydrogen peroxide oxygen radicals present at the wound site, triggering NF-KB to enhance the inflammatory response. 2, 8 New Zealand honeys have been suggested to display significant antiinflammatory activity, particularly kanuka and manuka honeys, by reducing neutrophil superoxide production. 23 Manuka honey has been shown to specifically decrease the inflammatory response associated with ulcerative colitis, an inflammatory bowel disease characterized by an overexpression of inflammatory cells, possibly by increasing antioxidant activity. 27−29 Several studies have investigated the anti-inflammatory activity of New Zealand honeys in treating topical wounds. This study further investigated the anti-inflammatory properties of manuka and kanuka honey, and demonstrates the effectiveness of these New Zealand honeys in reducing the inflammatory response associated with healing, independent of its known topical effect. Furthermore, specific signaling pathways, through which these honeys are effective, were observed.
Materials and methods

Preparation of honey extracts
Four New Zealand honeys were used -manuka, kanuka, a manuka/kanuka blend (all supplied by Comvita New Zealand Ltd, Te Puke, NZ), and clover honey (supplied by Airborne Honey Ltd, Leeston, NZ). Honey extracts were fractionated by Dr Peter Brooks (University of the Sunshine Coast, Sippy Downs, QLD, Australia) to isolate their phenolic compounds. The percentages of phenolics were determined (manuka 59%, kanuka 39%, the manuka/kanuka blend 59%, and clover 40%). They were stored at 4°C. Both phenolic and crude extracts were tested. Figure 1 depicts the process flow for the preparation of the following materials and the accompanying observation steps. reagents HEK-Blue™-2, HEK-Blue™-4, and nucleotide oligomerization domain (NOD)2-Wild Type (NOD2-WT) embryonic kidney cell lines were selected due to their accessibility and relatively high expression of matrix metalloproteinase (MMP)-1, -2, and -9. These were obtained from the Auckland Cancer Society Research Centre (Auckland, NZ). Dulbecco's Modified Eagle's Medium (DMEM), an antibiotic mixture ( penicillin, streptomycin, L-glutamine), and fetal calf serum (FCS) were obtained from Life Technologies Corp ( Carlsbad, CA, USA). Phorbol 12-myristate 13-acetate (PMA) and ibuprofen were purchased from Sigma-Aldrich Corp (St Louis, MO, USA). Lipopolysaccharide (LPS), Pam3CysSerLys4 (Pam3CSK4), and FSL-1 ( Pam2CGDPKHPKSF, a synthetic diacylated lipoprotein), Muramyl dipeptide (MDP), Blasticidin, Zeocin™, HEK-Blue™ Selection, and QUANTI-Blue™ were from InvivoGen (San Diego, CA, USA). Cell Proliferation Reagent WST-1 was obtained from Roche Applied Science (Penzberg, Germany).
cell culture
The HEK-Blue™-2 and HEK-Blue™-4 cells were maintained in DMEM high glucose supplemented with 10% FCS, 1% penicillin/streptomycin/glutamine, and HEK-Blue™ Selection. The NOD2 WT cells were maintained in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin, 0.06% Blasticidin, and 0.1% Zeocin.
Anti-inflammatory assay
The HEK-Blue™-2 and HEK-Blue™-4 cells were seeded at 1 × 10 5 cells/mL and the NOD2 WT cells at 5 × 10 5 cells/mL, into 96-well plates, and incubated for 24 hours at 37°C, 5% CO 2 . The honey extracts, at a suitable dose range (5.3%−14.3%) as determined by preliminary half maximal inhibitory concentration (IC 50 ) data, and the controls (75 mM Ibuprofen, 1 mg/mL PMA, and a solvent control) were added to the plate and further incubated for 24 hours. The appropriate ligand for each cell line was added (3.125 µg/mL LPS, 10 ng/mL Pam3CSK4, 10 ng/mL FSL-1, and 22.73 µg/mL MDP), and all were incubated for 24 hours. The secreted embryonic alkaline phosphatase (SEAP) production was measured, using QUANTI-Blue, every 10 minutes for 50 minutes. Cell viability was determined by WST-1 after 60-, 90-, and 120-minute incubations. The results were normalized for cell viability and against a solvent control. 
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Pathway of anti-inflammatory effect by New Zealand honeys statistical analysis A generalized linear model was fitted to test the antiinflammatory effect of eight honey extracts at five different concentrations (% honey) compared with untreated cells, in the presence of the specific ligand corresponding to the cell line. The means with standard error and estimates with 95% confidence interval along with P-value were calculated. Table 1 provides the anti-inflammatory effect of the honey extracts at five different concentrations (% honey) compared with untreated cells, in the HEK-Blue™-4 cell line using the LPS ligand. Table 2 provides the anti-inflammatory effect of the honey extracts at five different concentrations compared with untreated cells, in the HEK-Blue™-2 cell line using the FSL-1 ligand. Table 3 provides the anti-inflammatory effect of the honey extracts at five different concentrations compared with untreated cells, in the HEK-Blue™-2 cell line using the Pam3CSK4 ligand. Table 4 provides the anti-inflammatory effect of the honey extracts at five different concentrations compared with untreated cells, in the NOD2-WT cell line using the MDP ligand. Figure 1 provides the materials, preparation, and observation process flow. Figure 2 provides the anti-inflammatory effect of the four honey extracts when differentiated by honey phenolic and crude honey extract. The units were expressed as SEAP relative to the control (%). The higher the value, the higher was the level of SEAP, resulting in a lower anti-inflammatory effect. A P-value of less than 0.05 indicated that a significant anti-inflammatory effect was observed in those cells treated with honey compared with those cells that were not. All analyses were carried out using SAS ® 9.3 (SAS Institute, Cary, NC, USA).
Results
Effect of honey extracts on inflammation in heK-Blue™-4 cells
The honey extracts were analyzed in the HEK-Blue™-4 cell line in the presence of LPS. Plates incubated for 24 hours (37°C, 5% CO 2 )
Plates centrifuged at 2,000 rpm for 1 minute and left covered at room temperature 
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Tomblin et al anti-inflammatory effect. No substantive effect was observed with treatment by any of the extracts. Following an increase in honey concentration, a noticeable anti-inflammatory effect was observed with the higher concentrations of the phenolic and crude kanuka extracts. The manuka phenolic extract produced a significant effect at the 7.1% (P=0.0131) and 14.3% (P=0.0024) concentrations. No significant difference was observed between both the manuka/kanuka blend and clover honeys and untreated cells at any concentration, with the exception of the 12.5% concentration of the phenolic clover extract (P=0.0360). Tables 2 and 3 detail the effect of the honey extracts on the inflammatory response in the HEKBlue™-2 cells. By examining honey treatment using two ligands, the specific pathway through which honey might act could 
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Pathway of anti-inflammatory effect by New Zealand honeys reduced the level of inflammation compared with that of no treatment. Treatment with the manuka/kanuka blend, the clover honey phenolics, and the crude extracts from all four honeys had no significant impact on the inflammatory response. Figure 2 illustrates the anti-inflammatory effect observed using the HEK-Blue™-2 cell line when treated with the highest concentration (14.3%) of honey phenolics and crude extracts and stimulated with Pam3CSK4. A significant decrease in inflammation was observed for each Table 4 The anti-inflammatory effect of honey extracts at five different concentrations (% honey) compared with untreated cells, in the nOD2-WT cell line using the MDP ligand Effect of honey extracts on inflammation in nOD2-WT cells Table 4 details the anti-inflammatory effect of honey treatment in NOD2-WT cells. There was no significant effect by the honeys, at any concentration, on the inflammatory response when compared with no treatment, with the exception of the 12.5% concentration of the crude clover extract, where a significant anti-inflammatory effect was observed (P=0.0442).
Discussion
An inflammatory response was induced in HEK-Blue™-2, HEK-Blue™-4, and NOD2-WT cell lines using different ligands, to illustrate whether treatment with four honeys could produce an anti-inflammatory effect. The cell lines act through different signaling pathways (TLR2, TLR4, and NOD-like receptor [NLR] respectively). Thus, by being able to observe in which cell line(s) the honey treatment was effective, the pathway through which it produced an anti-inflammatory response could be demonstrated. The NOD2-WT cell line acts through the NLR signaling pathway and recognizes the MDP ligand. A substantial body of research exists to support the anti-inflammatory activity of a variety of honeys. This research, however, demonstrated that the honeys examined did not produce a significant antiinflammatory effect via either the TLR4 or NLR signaling pathway, observing a noticeable but not significant antiinflammatory activity with honey treatment. Anti-inflammatory activity with honey treatment was observed in the HEK-Blue™-2 cell line and most significantly with kanuka honey. The kanuka phenolic extract was highly anti-inflammatory and had a greater effect than did the crude extract, indicating that a higher phenolic content correlates with its elevated anti-inflammatory activity. The manuka honey phenolics also had an anti-inflammatory effect in the HEK-Blue™-2 cells, although to a lesser extent than for the kanuka honey phenolics, with the highest concentrations producing a significant difference as compared with no treatment, thereby supporting the importance of polyphenols in the anti-inflammatory activity of honey. The anti-inflammatory effect by the kanuka and manuka honeys was strongest in the presence of the Pam3CSK4 ligand, indicating that the honeys act through the TLR1/ TLR2 signaling pathway. 30 The anti-inflammatory activity of kanuka and manuka honeys is therefore pathway-specific. No significant effect was observed with honey treatment, at any concentration, in the NOD2-WT cell line, supporting the anti-inflammatory activity of honey being pathwayspecific. A hypothesis for the means by which kanuka honey exhibits anti-inflammatory activity is through the downregulation of proinflammatory mediators, such as IL-1β and NF-KB.
In wound healing, the inflammatory response is one phase of repair that is fundamental for normal healing. An elevated or prolonged inflammatory response is associated with a delay in wound repair, an increase in tissue damage, and the development of nonhealing, chronic wounds. By demonstrating significant anti-inflammatory activity, kanuka honey has the potential to be an effective treatment in preventing chronic wounds. International studies have shown that honey has a significant effect on the inflammatory response and support the use of honey in wound healing. 18, 24, 31 Research has also shown a causal association between inflammatory diseases and treatment with honey. 27, 29, 32 This study sought to investigate and further advance these findings. Antiinflammatory assays were conducted using HEK-Blue™-2, HEK-Blue™-4, and NOD2-WT cell lines, acting through different signaling pathways. The results demonstrate that kanuka honey exhibits anti-inflammatory effects in a pathway-specific manner. Further investigation would help to discover the exact mechanisms of action by which honeys act. 
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Pathway of anti-inflammatory effect by New Zealand honeys HEK-Blue™-2 is a more sensitive cell line than is HEK-Blue™-4. The noticeable but not significant antiinflammatory effect observed by the honey phenolics in the HEK-Blue™-4 cells contrasts with the significant impact in the HEK-Blue™-2 cells, suggesting a reduced sensitivity rather than no anti-inflammatory activity. Further investigation using larger volumes of honey would be required to determine whether more significant results could be obtained.
Conclusion
New Zealand honeys have a well-established antiinflammatory effect in topical wound healing. However, less was known of their effect in vitro and of the signaling pathways through which they act. Treatment with kanuka and manuka honeys resulted in powerful anti-inflammatory effects in HEK-Blue™-2 cells, but not in the HEK-Blue™-4 or NOD2-WT cells. Specifically, the anti-inflammatory effect occurred via the TLR1/TLR2 signaling pathway. The effects suggest a correlation with the phenolic content of the honeys, with a higher phenolic content producing an elevated anti-inflammatory effect. Kanuka and manuka honeys therefore can have a positive impact on the inflammatory response associated with wound healing. Subsequent investigation is needed to determine the specific compounds present in the honeys that are agents responsible for their anti-inflammatory activity.
